Evicenter
P&T meetings

Azetukalner (XEN1101)

Focal onset seizures

Regulatory submission
NDA submitted September 2026
Launch
Not announced
Last updated
163 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Focal onset seizures

Humanistic burden and health-related quality of life

6 evidence topics · 3 sources

Quality of life by treatment response in focal epilepsy
PopulationQuoted mean QOLIE-31-P total score with standard deviation
Focal epilepsy, drug resistant (n = 184)“56.4 (18.7)”
Focal epilepsy, drug responsive (n = 53)“70.8 (13.3)”
Comparison of the two groups“<0.0001”
Health utilities by seizure frequency in United States adults with focal epilepsy
Seizure frequency group, United States, unadjustedQuoted mean SF-6D health utility with standard deviation
Total sample (n = 345)“0.67 ± 0.14”
At least once a week (n = 55)“0.63 ± 0.14”
One to three times a month (n = 68)“0.65 ± 0.15”
One to four times a year (n = 71)“0.67 ± 0.13”
Less than once a year (n = 151)“0.70 ± 0.14”
p value for relationship to seizure frequency“0.006”